Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fractyl Health, Inc. - Common Stock (NQ: GUTS )

1.790 -0.030 (-1.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Fractyl Health, Inc. - Common Stock

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Participate in the Upcoming December Conferences
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Participate in Upcoming September Investor Conferences
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
Company will discuss recent corporate updates, including compelling preclinical data from Rejuva® pancreatic gene therapy platform, which was named top abstract at American Diabetes Association’s 84th... 
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
Management to host in-person KOL event and webcast at ADA on Monday, June 24, 2024, at 7:00 a.m. ET 
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
From Fractyl Health, Inc.
Via GlobeNewswire
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
From Fractyl Health, Inc.
Via GlobeNewswire
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
From Fractyl Health, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.